Cyclosporine ophthalmic emulsion
Dry eye · Rx
RxDry eyeDry Eye RxPreservative-free option
| Strength | 0.05% (Restasis), 0.09% (Cequa), 0.1% (Vevye) |
|---|---|
| Typical quantity | 0.4 mL vials, 60/box (generic ~$56-60; Cequa/Vevye $300-900) |
| Cash cost / month | Moderate · ~$20-100 |
| Drug class | Immunomodulator, calcineurin inhibitor |
| Mechanism of action | Calcineurin inhibitor; blocks T-cell activation and IL-2 transcription, reducing ocular surface inflammation and increasing goblet-cell density and tear production. |
| Indication / reason for use | Chronic DED with an inflammatory component; increases tear production where suppressed by keratoconjunctivitis sicca. Verkazia/Vevye for vernal keratoconjunctivitis. |
| Usual adult dosing | 1 drop in each eye twice daily, ~12 h apart. Onset of benefit typically 1-3 months. |
| Preservative | Preservative-free single-use vials (Restasis MultiDose bottle uses a PF valve) , a preservative-free option exists |
| Contact lenses | Remove lenses before instillation; may reinsert 15 minutes later. |
| Common / important adverse effects | Burning/stinging on instillation (common, transient), conjunctival hyperemia, foreign-body sensation. |
| Contraindications & cautions | Active ocular infection; caution with herpetic keratitis history. |
| Pregnancy / lactation | Limited data; systemic levels typically undetectable. Use if clearly needed. |
| Trade names | Restasis, Cequa, Vevye, Verkazia (VKC) |
| Practice notes | Set expectations about delayed onset and initial stinging to aid adherence; a short topical steroid pulse can bridge the first weeks. |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.